TNFRSF11A and Miyoshi myopathy: In this review, we discuss the mechanisms of MM-related SREs, and summarize current antiresorptive therapies such as bisphosphonate (BP) and the denosumab monoclonal antibody (moAb) -targeting receptor activator of nuclear factor-kappa B (NF-κB) ligand (RANKL) and anti-MM therapies, which include autologous stem cell transplantation (ASCT) and bortezomib-based regimens to prevent MBD.